Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis | Zendy

Timothy R. Betts | Zendy; Praveen P. Sadarmin | Zendy; David R. Tomlinson | Zendy; Kim Rajappan | Zendy; Kelvin CK Wong | Zendy; Joseph de Bono | Zendy; Y. Bashir | Zendy

Open Access

Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis

Author(s) -

Timothy R. Betts,

Praveen P. Sadarmin,

David R. Tomlinson,

Kim Rajappan,

Kelvin CK Wong,

Joseph de Bono,

Y. Bashir

Publication year - 2013

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/eus427

Subject(s) - medicine , number needed to treat , absolute risk reduction , relative risk , confidence interval , odds ratio , clinical trial , clinical endpoint , subgroup analysis

Absolute risk reduction (ARR) and number needed to treat (NNT) are considered by many to be the most appropriate figures to use for the informed consent process, yet the results of published implantable cardioverter defibrillators (ICD) trials are frequently presented as relative risk reduction or odds ratio. The period over which risk reduction is calculated also varies between trials, making comparison difficult.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research